Trial Condition(s):

Clinical Pharmacology

Finerenone / verapamil drug-drug interaction study

Bayer Identifier:

16910

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2015-001465-58

Study Completed

Trial Purpose

The primary objective of this study was
• to investigate the influence of multiple oral doses of verapamil 240 mg once-daily on the pharmacokinetics of 5 mg finerenone given as a single oral dose in comparison to 5 mg finerenone given alone
The secondary objectives were
• to assess the safety and tolerability of the combined administration of both drugs

Inclusion Criteria
- Healthy male white subjects between 18 and 45 years of age (inclusive) and a body mass index ≥18 and ≤29.9 kg/ m²
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
13
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
Kerendia (Finerenone, BAY94-8862)
Accepts Healthy Volunteers
Yes

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Berlin, Germany, 13353

Status
Completed
 

Trial Design